Drug-patents-expiring-in-2024
1. Abilify patent expiration
ABILIFY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7115587 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(10 months ago) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(11 months ago) | |
| US7550445 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(10 months ago) | |
|
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| New Indication(I-616) | Nov 19, 2012 |
| New Indication(I-633) | Feb 16, 2014 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 20 September, 2006
Treatment: Treatment of schizophrenia
Dosage: INJECTABLE; TABLET, ORALLY DISINTEGRATING; TABLET
How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage
ABILIFY family patents
2. Abilify Maintena Kit patent expiration
ABILIFY MAINTENA KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7807680 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(7 months ago) | |
| US8722679 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(7 months ago) | |
| US8030313 | OTSUKA PHARM CO LTD | Controlled release sterile injectable aripiprazole formulation and method |
Oct, 2024
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 28, 2016 |
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE
How can I launch a generic of ABILIFY MAINTENA KIT before it's drug patent expiration?
More Information on Dosage
ABILIFY MAINTENA KIT family patents
3. Abilify Mycite Kit patent
expiration
ABILIFY MYCITE KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
ABILIFY MYCITE KIT family patents
4. Abraxane patent expiration
ABRAXANE's oppositions filed in EPO
ABRAXANE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7820788 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Oct, 2024
(7 months ago) | |
|
US7923536 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(11 months ago) | |
|
US8138229 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(11 months ago) | |
|
US8314156 (Pediatric) | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-658) | Oct 11, 2015 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| M(M-14) | Dec 06, 2022 |
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of pancreatic cancer
Dosage: POWDER
How can I launch a generic of ABRAXANE before it's drug patent expiration?
More Information on Dosage
ABRAXANE family patents
5. Acular Ls patent expiration
Can you believe ACULAR LS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216127 | ABBVIE | Burial vault and method for customizing a burial vault |
May, 2024
(1 year, 2 days ago) | |
| US9216167 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 days ago) | |
| US8906950 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 days ago) | |
| US8946281 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 days ago) | |
| US8541463 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 days ago) | |
| US8648107 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 days ago) | |
| US8377982 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 days ago) | |
|
US8207215 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(6 months ago) | |
|
US8377982 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(6 months ago) | |
|
US8541463 (Pediatric) | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
Nov, 2024
(6 months ago) | |
| US8207215 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2024
(1 year, 2 days ago) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating ocular pain and/or enhancing ocular comfort; A method of treating or preventing ocular pain and burning; A method of treating ocular pain; A method of treating or reducing ocular ...
Dosage: SOLUTION/DROPS
How can I launch a generic of ACULAR LS before it's drug patent expiration?
More Information on Dosage
ACULAR LS family patents
6. Acuvail patent expiration
ACUVAIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8992952 | ABBVIE | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 22, 2012 |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 22 July, 2009
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of ACUVAIL before it's drug patent expiration?
More Information on Dosage
ACUVAIL family patents
7. Adasuve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8991387 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(1 year, 9 days ago) | |
| US9370629 | ALEXZA PHARMS | Self-contained heating unit and drug-supply unit employing same |
May, 2024
(1 year, 10 days ago) | |
| US7458374 | ALEXZA PHARMS | Method and apparatus for vaporizing a compound |
Aug, 2024
(9 months ago) | |
| US7537009 | ALEXZA PHARMS | Method of forming an aerosol for inhalation delivery |
Oct, 2024
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 21, 2015 |
Drugs and Companies using LOXAPINE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: NA
Dosage: POWDER
More Information on Dosage
ADASUVE family patents
8. Admelog Solostar patent expiration
ADMELOG SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8556864 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9233211 | SANOFI-AVENTIS US | Relating to a pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US8603044 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9623189 | SANOFI-AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9604009 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US8992486 | SANOFI-AVENTIS US | Pen-type injector |
Jun, 2024
(11 months ago) | |
| US9610409 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9775954 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9604008 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9526844 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9408979 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9011391 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9533105 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9561331 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9827379 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US8512297 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2020 |
Drugs and Companies using INSULIN LISPRO ingredient
Market Authorisation Date: 11 December, 2017
Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve; Improvement in glycemic control in diabetes mellitus patients by use of a pen injec...
Dosage: SOLUTION
More Information on Dosage
ADMELOG SOLOSTAR family patents
9. Airduo Digihaler patent expiration
AIRDUO DIGIHALER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9987229 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(8 months ago) | |
| US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO DIGIHALER family patents
10. Airduo Respiclick patent expiration
AIRDUO RESPICLICK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(8 months ago) | |
| US9987229 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER
More Information on Dosage
AIRDUO RESPICLICK family patents
11. Aldara patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7696159 | BAUSCH | Treatment for basal cell carcinoma |
Apr, 2024
(1 year, 1 month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7696159 (Pediatric) | BAUSCH | Treatment for basal cell carcinoma |
Oct, 2024
(7 months ago) | |
Drugs and Companies using IMIQUIMOD ingredient
Market Authorisation Date: 27 February, 1997
Treatment: Works through the induction of interferon and other cytokines
Dosage: CREAM
How can I launch a generic of ALDARA before it's drug patent expiration?
More Information on Dosage
ALDARA family patents
12. Aliqopa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7511041 | BAYER HEALTHCARE | Fused azole-pyrimidine derivatives |
May, 2024
(1 year, 17 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 14, 2022 |
| Orphan Drug Exclusivity(ODE) | Sep 14, 2024 |
| Orphan Drug Exclusivity(ODE-155) | Sep 14, 2024 |
Drugs and Companies using COPANLISIB DIHYDROCHLORIDE ingredient
NCE-1 date: 14 September, 2021
Market Authorisation Date: 14 September, 2017
Treatment: NA
Dosage: POWDER
More Information on Dosage
ALIQOPA family patents
13. Aloxi patent expiration
ALOXI's oppositions filed in EPO
ALOXI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9125905 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
| US8598219 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
|
US8598219 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
| US9066980 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
| US8729094 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
| US9457021 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
| US7947725 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
| US7960424 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
| US8518981 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
| US9439854 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
| US8598218 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
| US9173942 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
| US9457020 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
| US7947724 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(1 year, 3 months ago) | |
|
US7947724 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
|
US7947725 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
|
US7960424 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
|
US8729094 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
|
US8518981 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
|
US8598218 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
|
US9173942 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
|
US9125905 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
|
US9439854 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
|
US9457020 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
|
US9457021 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
|
US9066980 (Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 22, 2011 |
| New Indication(I-684) | May 27, 2017 |
| M(M-136) | May 27, 2017 |
| Pediatric Exclusivity(PED) | Nov 27, 2017 |
Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 29 February, 2008
Treatment: Prevention of chemotherapy-induced nausea and vomiting
Dosage: INJECTABLE
How can I launch a generic of ALOXI before it's drug patent expiration?
More Information on Dosage
ALOXI family patents
14. Alphagan P patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8858961 (Pediatric) | ABBVIE | Compositions containing alpha-2-adrenergic agonist components |
Mar, 2024
(1 year, 2 months ago) | |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 19 August, 2005
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of ALPHAGAN P before it's drug patent expiration?
More Information on Dosage
ALPHAGAN P family patents
15. Altabax patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8207191 | ALMIRALL | Process, salts, composition and use |
Aug, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2012 |
Drugs and Companies using RETAPAMULIN ingredient
NCE-1 date: 13 April, 2011
Market Authorisation Date: 12 April, 2007
Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes
Dosage: OINTMENT
More Information on Dosage
ALTABAX family patents
16. Amitiza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7795312 | SUCAMPO PHARMA LLC | Method for treating abdominal discomfort |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-670) | Apr 19, 2016 |
| M(M-225) | Apr 26, 2021 |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 29 April, 2008
Treatment: Method for treating irritable bowel syndrome and method for treating abdominal discomfort associated with irritable bowel syndrome
Dosage: CAPSULE
How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage
AMITIZA family patents
17. Ampyra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9918973 | MERZ | Sustained release aminopyridine composition |
Dec, 2024
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2015 |
| Orphan Drug Exclusivity(ODE) | Jan 22, 2017 |
Drugs and Companies using DALFAMPRIDINE ingredient
NCE-1 date: 22 January, 2014
Market Authorisation Date: 22 January, 2010
Treatment: Improvement of walking in patients with multiple sclerosis (ms)
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage
AMPYRA family patents
18. Anjeso patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10463673 | BAUDAX | Nanoparticulate meloxicam formulations |
Feb, 2024
(1 year, 3 months ago) | |
| US10471067 | BAUDAX | Nanoparticulate meloxicam formulations |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 20, 2023 |
Drugs and Companies using MELOXICAM ingredient
Market Authorisation Date: 20 February, 2020
Treatment: Management of moderate-to-severe pain by intravenous injection
Dosage: SOLUTION
More Information on Dosage
ANJESO family patents
19. Apidra Solostar patent expiration
APIDRA SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9623189 | SANOFI AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9827379 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9533105 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9604009 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9408979 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US8603044 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9775954 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9610409 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9011391 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9604008 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9526844 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US8556864 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US8992486 | SANOFI AVENTIS US | Pen-type injector |
Jun, 2024
(11 months ago) | |
| US8512297 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2024
(8 months ago) | |
| US9233211 | SANOFI AVENTIS US | Relating to a pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9561331 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 24, 2011 |
Drugs and Companies using INSULIN GLULISINE RECOMBINANT ingredient
Market Authorisation Date: 16 April, 2004
Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glycemic control in diabetes mellitus patients by use of a pen injec...
Dosage: INJECTABLE
More Information on Dosage
APIDRA SOLOSTAR family patents
20. Arikayce Kit patent expiration
ARIKAYCE KIT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9827317 | INSMED INC | Sustained release of antiinfectives |
Apr, 2024
(1 year, 1 month ago) | |
| US8802137 | INSMED INC | Sustained release of antiinfectives |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-214) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen; Treating mycobacterium avium complex (mac) lung disease in adults as part of a co...
Dosage: SUSPENSION, LIPOSOMAL
More Information on Dosage
ARIKAYCE KIT family patents
21. Armonair Digihaler patent expiration
ARMONAIR DIGIHALER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR DIGIHALER family patents
22. Armonair Respiclick patent expiration
ARMONAIR RESPICLICK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9616024 | TEVA PHARM | Process for preparing a medicament |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER
More Information on Dosage
ARMONAIR RESPICLICK family patents
23. Atripla patent expiration
ATRIPLA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8716264 (Pediatric) | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jul, 2024
(10 months ago) | |
| US8716264 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US9457036 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US8592397 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US9744181 | GILEAD SCIENCES | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
Drugs and Companies using EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 12 July, 2006
Treatment: Treatment of hiv infection; Treatment of hiv-1 infection in adults
Dosage: TABLET
How can I launch a generic of ATRIPLA before it's drug patent expiration?
More Information on Dosage
ATRIPLA family patents
24. Auryxia patent expiration
AURYXIA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9328133 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 3 months ago) | |
| US8338642 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 3 months ago) | |
| US9757416 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 3 months ago) | |
| US7767851 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846976 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 3 months ago) | |
| US8901349 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 3 months ago) | |
| US8609896 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 3 months ago) | |
| US8299298 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Feb, 2024
(1 year, 3 months ago) | |
| US8754258 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 3 months ago) | |
| US8754257 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 3 months ago) | |
| US9050316 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-790) | Nov 06, 2020 |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorous levels
Dosage: TABLET
More Information on Dosage
AURYXIA family patents
25. Auvi-q patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8920377 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US9833573 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 17 November, 2017
Treatment: Method to treat severe allergic emergencies in patients weighing 7.5 to 15 kg (16.5 to 33 lbs)
Dosage: SOLUTION
More Information on Dosage
AUVI-Q family patents
26. Belviq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8946207 | EISAI INC | Processes for preparing 3-benzazepines |
Jun, 2024
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 27 June, 2012
Treatment: NA
Dosage: TABLET
How can I launch a generic of BELVIQ before it's drug patent expiration?
More Information on Dosage
BELVIQ family patents
27. Belviq Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8946207 | EISAI INC | Processes for preparing 3-benzazepines |
Jun, 2024
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
Drugs and Companies using LORCASERIN HYDROCHLORIDE ingredient
NCE-1 date: 27 June, 2016
Market Authorisation Date: 15 July, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of BELVIQ XR before it's drug patent expiration?
More Information on Dosage
BELVIQ XR family patents
28. Bosulif patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE42376 | PF PRISM CV | Substituted 3-cyanoquinolines |
Apr, 2024
(1 year, 1 month ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
USRE42376 (Pediatric) | PF PRISM CV | Substituted 3-cyanoquinolines |
Oct, 2024
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Sep 04, 2019 |
| Orphan Drug Exclusivity(ODE-30) | Sep 04, 2019 |
| New Indication(I-759) | Dec 19, 2020 |
| Orphan Drug Exclusivity(ODE-163) | Dec 19, 2024 |
| New Indication(I-923) | Sep 26, 2026 |
| New Product(NP) | Sep 26, 2026 |
| Pediatric Exclusivity(PED) | Mar 26, 2027 |
| Orphan Drug Exclusivity(ODE-444) | Sep 26, 2030 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
NCE-1 date: 26 March, 2026
Market Authorisation Date: 04 September, 2012
Treatment: NA
Dosage: TABLET; CAPSULE
How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage
BOSULIF family patents
29. Brilinta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46276 | ASTRAZENECA | Triazolo(4,5-D)pyrimidine compounds |
Oct, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2016 |
| New Indication(I-714) | Sep 03, 2018 |
| New Strength(NS) | Sep 03, 2018 |
| New Indication(I-851) | May 28, 2023 |
| New Indication(I-848) | Nov 05, 2023 |
| M(M-283) | May 09, 2025 |
| Pediatric Exclusivity(PED) | Nov 09, 2025 |
Drugs and Companies using TICAGRELOR ingredient
NCE-1 date: 09 November, 2024
Market Authorisation Date: 03 September, 2015
Treatment: Reduction of the rate of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events
Dosage: TABLET
How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage
BRILINTA family patents
30. Bydureon patent expiration
BYDUREON's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 1 month ago) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 1 month ago) | |
|
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(7 months ago) | |
|
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2015 |
| M(M-162) | Sep 24, 2018 |
| M(M-212) | Oct 20, 2020 |
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiab...
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON family patents
31. Bydureon Bcise patent expiration
BYDUREON BCISE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 1 month ago) | |
|
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(7 months ago) | |
|
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(7 months ago) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 20, 2020 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiab...
Dosage: SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON BCISE family patents
32. Bydureon Pen patent expiration
BYDUREON PEN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 1 month ago) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 1 month ago) | |
|
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(7 months ago) | |
|
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-224) | Apr 02, 2021 |
| M(M-240) | Feb 15, 2022 |
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
BYDUREON PEN family patents
33. Cabometyx patent expiration
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8497284 | EXELIXIS INC | C-met modulators and method of use |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-760) | Dec 19, 2020 |
| New Indication(I-792) | Jan 14, 2022 |
| New Indication(I-854) | Jan 22, 2024 |
| New Indication(I-873) | Sep 17, 2024 |
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of advanced renal cell carcinoma
Dosage: TABLET
How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage
CABOMETYX family patents
34. Children's Advil Allergy Sinus patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238640 | HALEON US HOLDINGS | Pharmaceutical suspension composition |
May, 2024
(1 year, 5 days ago) | |
Market Authorisation Date: 24 February, 2004
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
CHILDREN'S ADVIL ALLERGY SINUS family patents
35. Children's Advil-flavored patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10238640 | HALEON US HOLDINGS | Pharmaceutical suspension composition |
May, 2024
(1 year, 5 days ago) | |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 27 June, 1996
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
CHILDREN'S ADVIL-FLAVORED family patents
36. Chloraprep One-step patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6991394 | BECTON DICKINSON CO | Liquid applicator with a mechanism for fracturing multiple ampoules |
Jan, 2024
(1 year, 3 months ago) | |
Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 14 July, 2000
Treatment: NA
Dosage: SPONGE
More Information on Dosage
CHLORAPREP ONE-STEP family patents
37. Chloraprep With Tint patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6991393 | BECTON DICKINSON CO | Liquid applicator for coloring a liquid |
Jan, 2024
(1 year, 3 months ago) | |
| US6991394 | BECTON DICKINSON CO | Liquid applicator with a mechanism for fracturing multiple ampoules |
Jan, 2024
(1 year, 3 months ago) | |
Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 14 July, 2000
Treatment: NA
Dosage: SPONGE
More Information on Dosage
CHLORAPREP WITH TINT family patents
38. Chlorhexidine Gluconate patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7066916 | SAGE PRODS | Disinfectant delivery system, and method of providing alcohol-free disinfection |
Feb, 2024
(1 year, 3 months ago) | |
Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient
Market Authorisation Date: 25 April, 2005
Treatment: Disinfection of patient skin prior to an invasive procedure
Dosage: CLOTH
More Information on Dosage
CHLORHEXIDINE GLUCONATE family patents
39. Combivent Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2014 |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage
COMBIVENT RESPIMAT family patents
40. Complera patent expiration
COMPLERA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8716264 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jul, 2024
(10 months ago) | |
| US9457036 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US8716264 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US9744181 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US8592397 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
| New Patient Population(NPP) | Dec 13, 2016 |
NCE-1 date: 21 May, 2015
Market Authorisation Date: 10 August, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of COMPLERA before it's drug patent expiration?
More Information on Dosage
COMPLERA family patents
41. Contrave patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815889 | NALPROPION | Compositions and methods for increasing insulin sensitivity |
Jul, 2024
(10 months ago) | |
| US11278544 | NALPROPION | Compositions for affecting weight loss |
Apr, 2024
(1 year, 1 month ago) | |
| US7462626 | NALPROPION | Compositions for affecting weight loss |
Jul, 2024
(10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For effect on blood glucose parameters in patients with insulin resistance; For chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of CONTRAVE before it's drug patent expiration?
More Information on Dosage
CONTRAVE family patents
42. Daliresp patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8536206 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 2 months ago) | |
| US8604064 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 2 months ago) | |
| US8618142 | ASTRAZENECA | Process for the preparation of roflumilast |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2016 |
| M(M-208) | Aug 31, 2020 |
| New Dosing Schedule(D-171) | Jan 23, 2021 |
| New Strength(NS) | Jan 23, 2021 |
Drugs and Companies using ROFLUMILAST ingredient
NCE-1 date: 28 February, 2015
Market Authorisation Date: 23 January, 2018
Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations
Dosage: TABLET
How can I launch a generic of DALIRESP before it's drug patent expiration?
More Information on Dosage
DALIRESP family patents
43. Defencath patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8541393 | CORMEDIX | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
Nov, 2024
(6 months ago) | |
| US9339036 | CORMEDIX | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 15, 2033 |
Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient
NCE-1 date: 15 November, 2032
Market Authorisation Date: 15 November, 2023
Treatment: A catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter
Dosage: SOLUTION
More Information on Dosage
DEFENCATH family patents
44. Dexilant patent expiration
Can you believe DEXILANT received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(1 year, 1 month ago) | |
|
US8722084 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2012 |
| Pediatric Exclusivity(PED) | Jul 30, 2012 |
| New Patient Population(NPP) | Jul 08, 2019 |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 30 January, 2009
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of DEXILANT before it's drug patent expiration?
More Information on Dosage
DEXILANT family patents
45. Dexilant Solutab patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8784885 (Pediatric) | TAKEDA PHARMS USA | Controlled release preparation |
Apr, 2024
(1 year, 1 month ago) | |
Drugs and Companies using DEXLANSOPRAZOLE ingredient
Market Authorisation Date: 26 January, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
More Information on Dosage
DEXILANT SOLUTAB family patents
46. Dextenza patent expiration
DEXTENZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9254267 | OCULAR THERAPEUTIX | Composite hydrogel drug delivery systems |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 30, 2021 |
| New Indication(I-800) | Jun 20, 2022 |
| New Indication(I-876) | Oct 07, 2024 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: NA
Dosage: INSERT
More Information on Dosage
DEXTENZA family patents
47. Differin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7737181 | GALDERMA LABS LP | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
Aug, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Mar 17, 2013 |
| RTO(RTO) | Jul 08, 2019 |
Drugs and Companies using ADAPALENE ingredient
Market Authorisation Date: 19 June, 2007
Treatment: NA
Dosage: GEL
How can I launch a generic of DIFFERIN before it's drug patent expiration?
More Information on Dosage
DIFFERIN family patents
48. Dificid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8586551 (Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2016 |
| New Product(NP) | Jan 24, 2023 |
| New Patient Population(NPP) | Jan 24, 2023 |
| Pediatric Exclusivity(PED) | Jul 24, 2023 |
| Orphan Drug Exclusivity(ODE-367) | Jan 24, 2027 |
Drugs and Companies using FIDAXOMICIN ingredient
NCE-1 date: 24 July, 2022
Market Authorisation Date: 27 May, 2011
Treatment: NA
Dosage: TABLET; FOR SUSPENSION
How can I launch a generic of DIFICID before it's drug patent expiration?
More Information on Dosage
DIFICID family patents
49. Diprivan patent expiration
DIPRIVAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476010 | FRESENIUS KABI USA | Propofol formulations with non-reactive container closures |
Dec, 2024
(5 months ago) | |
Drugs and Companies using PROPOFOL ingredient
Market Authorisation Date: 02 October, 1989
Treatment: NA
Dosage: INJECTABLE
How can I launch a generic of DIPRIVAN before it's drug patent expiration?
More Information on Dosage
DIPRIVAN family patents
50. Duavee patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6479535 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
May, 2024
(1 year, 24 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 03, 2016 |
| New Chemical Entity Exclusivity(NCE) | Oct 13, 2018 |
Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient
NCE-1 date: 13 October, 2017
Market Authorisation Date: 03 October, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET
More Information on Dosage
DUAVEE family patents
51. Durysta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398707 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Apr, 2024
(1 year, 30 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT
More Information on Dosage
DURYSTA family patents
52. Dutrebis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7169780 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(1 year, 1 month ago) | |
Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 06 February, 2015
Treatment: NA
Dosage: TABLET
More Information on Dosage
DUTREBIS family patents
53. Dymista patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8163723 (Pediatric) | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 01, 2015 |
| New Patient Population(NPP) | Feb 20, 2018 |
| Pediatric Exclusivity(PED) | Aug 20, 2018 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 01 May, 2012
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of DYMISTA before it's drug patent expiration?
More Information on Dosage
DYMISTA family patents
54. Elelyso patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8741620 | PFIZER | Human lysosomal proteins from plant cell culture |
Feb, 2024
(1 year, 3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8227230 | PFIZER | Human lysosomal proteins from plant cell culture |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 01, 2017 |
| New Patient Population(NPP) | Aug 27, 2017 |
Drugs and Companies using TALIGLUCERASE ALFA ingredient
NCE-1 date: 01 May, 2016
Market Authorisation Date: 01 May, 2012
Treatment: NA
Dosage: POWDER
More Information on Dosage
ELELYSO family patents
55. Entresto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7468390 (Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
May, 2024
(1 year, 3 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2020 |
| New Patient Population(NPP) | Oct 01, 2022 |
| Pediatric Exclusivity(PED) | Apr 01, 2023 |
| M(M-82) | Feb 16, 2024 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
NCE-1 date: 01 April, 2022
Market Authorisation Date: 07 July, 2015
Treatment: NA
Dosage: TABLET
How can I launch a generic of ENTRESTO before it's drug patent expiration?
More Information on Dosage
ENTRESTO family patents
56. Envarsus Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8889186 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US8623411 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US8889185 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US8586084 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US10548880 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US8486993 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US9161907 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US11077096 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US8623410 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US8617599 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US9763920 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US9757362 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US7994214 | VELOXIS PHARMS INC | Solid dispersions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| US8591946 | VELOXIS PHARMS INC | Modified release compositions comprising tacrolimus |
Aug, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jul 10, 2022 |
| Orphan Drug Exclusivity(ODE-94) | Jul 10, 2022 |
Drugs and Companies using TACROLIMUS ingredient
Market Authorisation Date: 10 July, 2015
Treatment: Prophylaxis of organ rejection; Prophylaxis of organ rejection in de novo transplant patient
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ENVARSUS XR before it's drug patent expiration?
More Information on Dosage
ENVARSUS XR family patents
57. Epiduo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7964202 | GALDERMA LABS LP | Method for treatment of common acne |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Dec 08, 2011 |
| New Patient Population(NPP) | Feb 01, 2016 |
Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient
Market Authorisation Date: 08 December, 2008
Treatment: Treatment of acne
Dosage: GEL
How can I launch a generic of EPIDUO before it's drug patent expiration?
More Information on Dosage
EPIDUO family patents
58. Equetro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6977253 | VALIDUS PHARMS | Methods for the treatment of bipolar disorder using carbamazepine |
May, 2024
(1 year, 11 days ago) | |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 10 December, 2004
Treatment: The recommended initial dose of equetro is 400mg/day given in divided doses, twice daily. the dose should be adjusted in 200mg daily increments to achieve optimal clinical response.
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of EQUETRO before it's drug patent expiration?
More Information on Dosage
EQUETRO family patents
59. Evekeo Odt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10130580 | AZURITY | Taste-masked pharmaceutical compositions |
Apr, 2024
(1 year, 1 month ago) | |
Drugs and Companies using AMPHETAMINE SULFATE ingredient
Market Authorisation Date: 16 April, 2021
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING
More Information on Dosage
EVEKEO ODT family patents
60. Evoclin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7141237 | NORVIUM BIOSCIENCE | Pharmaceutical foam |
Feb, 2024
(1 year, 3 months ago) | |
| US7374747 | NORVIUM BIOSCIENCE | Pharmaceutical foam |
Jan, 2024
(1 year, 4 months ago) | |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 22 October, 2004
Treatment: Treatment of acne vulgaris
Dosage: AEROSOL, FOAM
How can I launch a generic of EVOCLIN before it's drug patent expiration?
More Information on Dosage
EVOCLIN family patents
61. Evzio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO family patents
62. Evzio (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
EVZIO (AUTOINJECTOR) family patents
63. Exservan patent expiration
EXSERVAN's oppositions filed in EPO
EXSERVAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8603514 | AQUESTIVE | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(1 year, 1 month ago) | |
| US8765167 | AQUESTIVE | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(1 year, 3 months ago) | |
Drugs and Companies using RILUZOLE ingredient
Market Authorisation Date: 22 November, 2019
Treatment: NA
Dosage: FILM
More Information on Dosage
EXSERVAN family patents
64. Farxiga patent expiration
FARXIGA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-157) | Mar 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| M(M-212) | Oct 20, 2020 |
| M(M-238) | Feb 22, 2022 |
| New Indication(I-841) | Oct 18, 2022 |
| New Indication(I-834) | May 05, 2023 |
| New Indication(I-857) | Apr 30, 2024 |
| M(M-298) | May 08, 2026 |
| New Patient Population(NPP) | Jun 12, 2027 |
| Pediatric Exclusivity(PED) | Dec 12, 2027 |
Drugs and Companies using DAPAGLIFLOZIN ingredient
NCE-1 date: 12 December, 2026
Market Authorisation Date: 08 January, 2014
Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide
Dosage: TABLET
How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage
FARXIGA family patents
65. Fenoglide patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8124125 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(7 months ago) | |
| US8481078 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(7 months ago) | |
| US7658944 | SALIX | Solid dosage form comprising a fibrate |
Dec, 2024
(5 months ago) | |
| US9173847 | SALIX | Tablet comprising a fibrate |
Oct, 2024
(7 months ago) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 10 August, 2007
Treatment: For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia; Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl...
Dosage: TABLET
How can I launch a generic of FENOGLIDE before it's drug patent expiration?
More Information on Dosage
FENOGLIDE family patents
66. Fentora patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8119158 | CEPHALON | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
Dec, 2024
(4 months ago) | |
| US8092832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Dec, 2024
(4 months ago) | |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 25 September, 2006
Treatment: NA
Dosage: TABLET
How can I launch a generic of FENTORA before it's drug patent expiration?
More Information on Dosage
FENTORA family patents
67. Fiasp Flextouch patent expiration
FIASP FLEXTOUCH's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 29, 2020 |
| New Patient Population(NPP) | Dec 19, 2022 |
Drugs and Companies using INSULIN ASPART ingredient
Market Authorisation Date: 29 September, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
FIASP FLEXTOUCH family patents
68. Finacea patent expiration
FINACEA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8435498 | LEO PHARMA AS | Penetrating pharmaceutical foam |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 29, 2018 |
Drugs and Companies using AZELAIC ACID ingredient
Market Authorisation Date: 29 July, 2015
Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea
Dosage: AEROSOL, FOAM
How can I launch a generic of FINACEA before it's drug patent expiration?
More Information on Dosage
FINACEA family patents
69. Flonase Sensimist Allergy Relief patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9320862 | HALEON US HOLDINGS | Fluid dispensing device |
Nov, 2024
(6 months ago) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
FLONASE SENSIMIST ALLERGY RELIEF family patents
70. Fosrenol patent expiration
FOSRENOL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7381428 | TAKEDA PHARMS USA | Stabilized lanthanum carbonate compositions |
Aug, 2024
(9 months ago) | |
| US7465465 | TAKEDA PHARMS USA | Pharmaceutical formulation comprising lanthanum compounds |
Aug, 2024
(9 months ago) | |
Drugs and Companies using LANTHANUM CARBONATE ingredient
Market Authorisation Date: 23 November, 2005
Treatment: Reduction of serum phosphate in patients with end stage renal disease
Dosage: POWDER; TABLET, CHEWABLE
How can I launch a generic of FOSRENOL before it's drug patent expiration?
More Information on Dosage
FOSRENOL family patents
71. Givlaari patent expiration
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9708610 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(1 year, 4 months ago) | |
| US11530408 | ALNYLAM PHARMS INC | Therapeutic compositions |
May, 2024
(1 year, 12 days ago) | |
| US9708615 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(1 year, 2 months ago) | |
| US10273477 | ALNYLAM PHARMS INC | Therapeutic compositions |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION
More Information on Dosage
GIVLAARI family patents
72. Gonal-f Rff Pen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7741268 | EMD SERONO | Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant |
Apr, 2024
(1 year, 1 month ago) | |
Drugs and Companies using FOLLITROPIN ALFA/BETA ingredient
Market Authorisation Date: 25 November, 2019
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
GONAL-F RFF PEN family patents
73. Gralise patent expiration
GRALISE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7438927 | ALMATICA | Methods of treatment using a gastric retained gabapentin dosage |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 28, 2014 |
| Orphan Drug Exclusivity(ODE) | Jan 28, 2018 |
| Orphan Drug Exclusivity(ODE-6) | Jan 28, 2018 |
Drugs and Companies using GABAPENTIN ingredient
Market Authorisation Date: 28 January, 2011
Treatment: Treatment with gabapentin, including treatment of neuropathic pain, including neuropathic pain associated with postherpetic neuralgia
Dosage: TABLET
How can I launch a generic of GRALISE before it's drug patent expiration?
More Information on Dosage
GRALISE family patents
74. Halaven patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6214865 (Pediatric) | EISAI INC | Macrocyclic analogs and methods of their use and preparation |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2015 |
| New Indication(I-721) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 28, 2023 |
| Orphan Drug Exclusivity(ODE-107) | Jan 28, 2023 |
| M(M-280) | Sep 13, 2025 |
| Pediatric Exclusivity(PED) | Mar 13, 2026 |
Drugs and Companies using ERIBULIN MESYLATE ingredient
NCE-1 date: 13 March, 2025
Market Authorisation Date: 15 November, 2010
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of HALAVEN before it's drug patent expiration?
More Information on Dosage
HALAVEN family patents
75. Humalog Kwikpen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | ELI LILLY AND CO | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(9 months ago) | |
Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient
Market Authorisation Date: 26 May, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
HUMALOG KWIKPEN family patents
76. Humalog Kwikpen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(9 months ago) | |
Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient
Market Authorisation Date: 15 November, 2019
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMALOG KWIKPEN family patents
77. Humalog Mix 50/50 Kwikpen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(9 months ago) | |
Market Authorisation Date: 22 December, 1999
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMALOG MIX 50/50 KWIKPEN family patents
78. Humalog Mix 75/25 Kwikpen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(9 months ago) | |
Market Authorisation Date: 22 December, 1999
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMALOG MIX 75/25 KWIKPEN family patents
79. Humulin 70/30 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(9 months ago) | |
Market Authorisation Date: 25 April, 1989
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMULIN 70/30 family patents
80. Humulin 70/30 Pen patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(9 months ago) | |
Market Authorisation Date: 25 April, 1989
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMULIN 70/30 PEN family patents
81. Humulin N patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(9 months ago) | |
Drugs and Companies using INSULIN SUSP ISOPHANE RECOMBINANT HUMAN ingredient
Market Authorisation Date: 28 October, 1982
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMULIN N family patents
82. Humulin R patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7291132 | LILLY | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NR(NR) | Mar 25, 2014 |
Drugs and Companies using INSULIN RECOMBINANT HUMAN ingredient
Market Authorisation Date: 29 December, 2015
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
HUMULIN R family patents
83. Hycamtin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8158645 | SANDOZ | Compound, corresponding compositions, preparation and/or treatment methods |
Dec, 2024
(5 months ago) | |
Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 11 October, 2007
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
HYCAMTIN family patents
84. Ilevro patent expiration
ILEVRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7947295 | HARROW EYE | Ophthalmic compositions containing a synergistic combination of two polymers |
Jun, 2024
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 16, 2015 |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 16 October, 2012
Treatment: NA
Dosage: SUSPENSION/DROPS
How can I launch a generic of ILEVRO before it's drug patent expiration?
More Information on Dosage
ILEVRO family patents
85. Inbrija patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7182961 | MERZ | Particulate compositions for pulmonary delivery |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 21, 2021 |
Drugs and Companies using LEVODOPA ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER
More Information on Dosage
INBRIJA family patents
86. Invokamet patent expiration
INVOKAMET's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| M(M-197) | Feb 01, 2020 |
| New Indication(I-788) | Oct 29, 2021 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 08 August, 2014
Treatment: NA
Dosage: TABLET
How can I launch a generic of INVOKAMET before it's drug patent expiration?
More Information on Dosage
INVOKAMET family patents
87. Invokamet Xr patent expiration
INVOKAMET XR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785403 | JANSSEN PHARMS | Glucopyranoside compound |
Jul, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Aug 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 29, 2018 |
| New Indication(I-735) | May 20, 2019 |
| New Indication(I-788) | Oct 29, 2021 |
| New Patient Population(NPP) | Dec 18, 2027 |
| Pediatric Exclusivity(PED) | Jun 18, 2028 |
Drugs and Companies using CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 19 June, 2027
Market Authorisation Date: 20 September, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of INVOKAMET XR before it's drug patent expiration?
More Information on Dosage
INVOKAMET XR family patents
88. Ionsys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6975902 | THE MEDICINES CO | Reservoir and a series of related reservoirs for use in an electrotransport drug delivery device and devices comprised thereof |
Apr, 2024
(1 year, 1 month ago) | |
Drugs and Companies using FENTANYL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 May, 2006
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
IONSYS family patents
89. Iqirvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7943661 | IPSEN | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof |
Sep, 2024
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7632870 | IPSEN | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 10, 2029 |
| Orphan Drug Exclusivity(ODE-486) | Jun 10, 2031 |
Drugs and Companies using ELAFIBRANOR ingredient
NCE-1 date: 10 June, 2028
Market Authorisation Date: 10 June, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
IQIRVO family patents
90. Isentress patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7169780 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Patient Population(NPP) | Nov 22, 2020 |
| M(M-114) | Mar 28, 2015 |
| New Dosing Schedule(D-167) | May 26, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: NA
Dosage: TABLET; TABLET, CHEWABLE; POWDER
How can I launch a generic of ISENTRESS before it's drug patent expiration?
More Information on Dosage
ISENTRESS family patents
91. Isentress Hd patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7169780 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 26, 2020 |
| New Patient Population(NPP) | Nov 22, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: NA
Dosage: TABLET
How can I launch a generic of ISENTRESS HD before it's drug patent expiration?
More Information on Dosage
ISENTRESS HD family patents
92. Ixempra Kit patent expiration
IXEMPRA KIT IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7312237 | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2012 |
| Pediatric Exclusivity(PED) | Apr 18, 2015 |
| M(M-61) | Oct 18, 2014 |
Drugs and Companies using IXABEPILONE ingredient
NCE-1 date: 18 April, 2014
Market Authorisation Date: 16 October, 2007
Treatment: Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer
Dosage: INJECTABLE
How can I launch a generic of IXEMPRA KIT before it's drug patent expiration?
More Information on Dosage
IXEMPRA KIT family patents
93. Kaletra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| US8309613 | ABBVIE | Solid pharmaceutical dosage form |
Dec, 2024
(5 months ago) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-124) | Apr 27, 2013 |
Drugs and Companies using LOPINAVIR; RITONAVIR ingredient
Market Authorisation Date: 09 November, 2007
Treatment: Treatment of hiv-1 infection in combination with other antiretroviral agents; Treatment of hiv-infection in combination with other antiretroviral agents
Dosage: TABLET
How can I launch a generic of KALETRA before it's drug patent expiration?
More Information on Dosage
KALETRA family patents
94. Kuvan patent expiration
KUVAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067416 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(6 months ago) | |
| USRE43797 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
Nov, 2024
(6 months ago) | |
| US7947681 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(6 months ago) | |
| US7566714 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(6 months ago) | |
| US7612073 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(6 months ago) | |
| US9433624 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(6 months ago) | |
| US7727987 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(6 months ago) | |
| US8318745 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 13, 2012 |
| Orphan Drug Exclusivity(ODE) | Dec 13, 2014 |
| New Patient Population(NPP) | Apr 23, 2017 |
| Pediatric Exclusivity(PED) | Oct 23, 2017 |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2013
Treatment: Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; Kuvan is indicated to reduce blood phenylalanine levels in patients with hyperphenylalaninemia; T...
Dosage: POWDER; TABLET
How can I launch a generic of KUVAN before it's drug patent expiration?
More Information on Dosage
KUVAN family patents
95. Kynmobi patent expiration
KYNMOBI's oppositions filed in EPO
KYNMOBI IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765167 | SUMITOMO PHARMA AM | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(1 year, 3 months ago) | |
| US8603514 | SUMITOMO PHARMA AM | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: NA
Dosage: FILM
More Information on Dosage
KYNMOBI family patents
96. Lantus patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7476652 (Pediatric) | SANOFI AVENTIS US | Acidic insulin preparations having improved stability |
Jan, 2024
(1 year, 4 months ago) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LANTUS family patents
97. Lantus Solostar patent expiration
LANTUS SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9408979 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9827379 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9011391 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9533105 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9604009 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9610409 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9233211 | SANOFI AVENTIS US | Relating to a pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9623189 | SANOFI AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9526844 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US8992486 | SANOFI AVENTIS US | Pen-type injector |
Jun, 2024
(11 months ago) | |
| US9561331 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US8512297 | SANOFI AVENTIS US | Pen-type injector |
Sep, 2024
(8 months ago) | |
| US8556864 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9604008 | SANOFI AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US8603044 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9775954 | SANOFI AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 27 April, 2007
Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glycemic control in diabetes mellitus patients by use of a pen injec...
Dosage: INJECTABLE
More Information on Dosage
LANTUS SOLOSTAR family patents
98. Latisse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7351404 | ABBVIE | Method of enhancing hair growth |
May, 2024
(1 year, 5 days ago) | |
| US8101161 | ABBVIE | Method of enhancing hair growth |
May, 2024
(1 year, 5 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 24, 2011 |
| M(M-140) | Sep 04, 2017 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 24 December, 2008
Treatment: Treatment of hypotrichosis of the eyelashes by increasing and stimulating their growth including length, thickness and darkness; Method of increasing hair growth
Dosage: SOLUTION/DROPS
How can I launch a generic of LATISSE before it's drug patent expiration?
More Information on Dosage
LATISSE family patents
99. Latuda patent expiration
LATUDA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815827 | SUNOVION PHARMS INC | Agent for treatment of schizophrenia |
Feb, 2024
(1 year, 3 months ago) | |
| US9174975 | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Feb, 2024
(1 year, 3 months ago) | |
|
US9174975 (Pediatric) | SUNOVION PHARMS INC | Remedy for integration dysfunction syndrome |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-134) | Apr 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
| New Indication(I-674) | Jun 28, 2016 |
| M(M-195) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| New Patient Population(NPP) | Mar 05, 2021 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Treatment: Treatment of major depressive episodes associated with bipolar i disorder; Treatment of schizophrenia with improvement in negative symptoms and/or cognitive dysfunction of schizophrenia
Dosage: TABLET
How can I launch a generic of LATUDA before it's drug patent expiration?
More Information on Dosage
LATUDA family patents
100. Lazanda patent expiration
LAZANDA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8216604 | BTCP PHARMA | Method of managing or treating pain |
Oct, 2024
(7 months ago) | |
| US8889176 | BTCP PHARMA | Method of managing or treating pain |
Jan, 2024
(1 year, 4 months ago) | |
| US9814705 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(1 year, 4 months ago) | |
| US9078814 | BTCP PHARMA | Intranasal spray device containing pharmaceutical composition |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Jun 30, 2014 |
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 30 June, 2011
Treatment: Management of breakthrough pain in patients with cancer
Dosage: SPRAY, METERED
More Information on Dosage
LAZANDA family patents
101. Leqvio patent expiration
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9708610 | NOVARTIS | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Jan, 2024
(1 year, 4 months ago) | |
| US11530408 | NOVARTIS | Therapeutic compositions |
May, 2024
(1 year, 12 days ago) | |
| US9708615 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 2 months ago) | |
| US10273477 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 2 months ago) | |
| US10669544 | NOVARTIS | Therapeutic compositions |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 22 December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (hefh), by inhibiting expression of the pcsk9 gen...
Dosage: SOLUTION
More Information on Dosage
LEQVIO family patents
102. Levemir Flextouch patent expiration
LEVEMIR FLEXTOUCH's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
LEVEMIR FLEXTOUCH family patents
103. Linzess patent expiration
LINZESS's oppositions filed in EPO
Can you believe LINZESS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7745409 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 4 months ago) | |
| US7704947 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 4 months ago) | |
| US8080526 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 4 months ago) | |
| US7371727 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ABBVIE | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 30, 2017 |
| New Strength(NS) | Jan 25, 2020 |
| New Indication(I-921) | Jun 12, 2026 |
Drugs and Companies using LINACLOTIDE ingredient
NCE-1 date: 30 August, 2016
Market Authorisation Date: 25 January, 2017
Treatment: Method of treating chronic idiopathic constipation in adult patients.
Dosage: CAPSULE
How can I launch a generic of LINZESS before it's drug patent expiration?
More Information on Dosage
LINZESS family patents
104. Livalo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7022713 | KOWA CO | Hyperlipemia therapeutic agent |
Feb, 2024
(1 year, 3 months ago) | |
| US8557993 | KOWA CO | Crystalline forms of pitavastatin calcium |
Feb, 2024
(1 year, 3 months ago) | |
|
US7022713 (Pediatric) | KOWA CO | Hyperlipemia therapeutic agent |
Aug, 2024
(9 months ago) | |
|
US8557993 (Pediatric) | KOWA CO | Crystalline forms of pitavastatin calcium |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2014 |
| New Patient Population(NPP) | May 16, 2022 |
| Pediatric Exclusivity(PED) | Nov 16, 2022 |
Drugs and Companies using PITAVASTATIN CALCIUM ingredient
NCE-1 date: 16 November, 2021
Market Authorisation Date: 03 August, 2009
Treatment: Adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemi...
Dosage: TABLET
How can I launch a generic of LIVALO before it's drug patent expiration?
More Information on Dosage
LIVALO family patents
105. Lonhala Magnair Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7458372 | SUMITOMO PHARMA AM | Inhalation therapy device |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 05, 2020 |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
LONHALA MAGNAIR KIT family patents
106. Lynparza patent expiration
LYNPARZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7981889 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(7 months ago) | |
| US7449464 | ASTRAZENECA | Phthalazinone derivatives |
Oct, 2024
(7 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8912187 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(1 year, 2 months ago) | |
| US9566276 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(1 year, 2 months ago) | |
| US9169235 | ASTRAZENECA | Phthalazinone derivatives |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| New Product(NP) | Aug 17, 2020 |
| New Indication(I-762) | Jan 12, 2021 |
| New Indication(I-776) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| New Indication(I-818) | Dec 27, 2022 |
| New Indication(I-831) | May 08, 2023 |
| New Indication(I-832) | May 19, 2023 |
| Orphan Drug Exclusivity(ODE-180) | Aug 17, 2024 |
| Orphan Drug Exclusivity(ODE-181) | Aug 17, 2024 |
| New Indication(I-885) | Mar 11, 2025 |
| Orphan Drug Exclusivity(ODE-226) | Dec 19, 2025 |
| New Indication(I-914) | May 31, 2026 |
| Orphan Drug Exclusivity(ODE-283) | Dec 27, 2026 |
| Orphan Drug Exclusivity(ODE-306) | May 08, 2027 |
Drugs and Companies using OLAPARIB ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; Maintenance treatment of ...
Dosage: CAPSULE; TABLET
How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage
LYNPARZA family patents
107. Mavenclad patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8785415 | EMD SERONO INC | Oral formulations of cladribine |
Apr, 2024
(1 year, 1 month ago) | |
| US7888328 | EMD SERONO INC | Oral formulations of cladribine |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 29, 2022 |
Drugs and Companies using CLADRIBINE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Treatment of ms with an admixture of (a) an amorphous inclusion complex of cladribine (2cda) and cyclodextrin and (b) amorphous free 2cda and cyclodextrin as a non-inclusion complex, formulated as a s...
Dosage: TABLET
How can I launch a generic of MAVENCLAD before it's drug patent expiration?
More Information on Dosage
MAVENCLAD family patents
108. Megace Es patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7101576 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(1 year, 1 month ago) | |
| US9101540 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(1 year, 1 month ago) | |
| US9040088 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(1 year, 1 month ago) | |
| US9101549 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(1 year, 1 month ago) | |
| US9107827 | ENDO OPERATIONS | Nanoparticulate megestrol formulations |
Apr, 2024
(1 year, 1 month ago) | |
Drugs and Companies using MEGESTROL ACETATE ingredient
Market Authorisation Date: 05 July, 2005
Treatment: Treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids)
Dosage: SUSPENSION
How can I launch a generic of MEGACE ES before it's drug patent expiration?
More Information on Dosage
MEGACE ES family patents
109. Methylin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7691880 | SPECGX LLC | Methylphenidate solution and associated methods of administration and production |
Oct, 2024
(7 months ago) | |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2002
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of METHYLIN before it's drug patent expiration?
More Information on Dosage
METHYLIN family patents
110. Mirvaso patent expiration
MIRVASO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859551 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2024
(1 year, 5 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2016 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Topical treatment of facial erythema of rosacea
Dosage: GEL
How can I launch a generic of MIRVASO before it's drug patent expiration?
More Information on Dosage
MIRVASO family patents
111. Movantik patent expiration
MOVANTIK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067431 | VALINOR | Chemically modified small molecules |
Dec, 2024
(5 months ago) | |
| US7056500 | VALINOR | Polymer conjugates of opioid antagonists |
Jun, 2024
(10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 16, 2019 |
Drugs and Companies using NALOXEGOL OXALATE ingredient
NCE-1 date: 16 September, 2018
Market Authorisation Date: 16 September, 2014
Treatment: Treatment of opioid-induced constipation
Dosage: TABLET
How can I launch a generic of MOVANTIK before it's drug patent expiration?
More Information on Dosage
MOVANTIK family patents
112. Moviprep patent expiration
MOVIPREP's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169381 | SALIX PHARMS | Colon cleansing compositions and methods |
Sep, 2024
(8 months ago) | |
| US7658914 | SALIX PHARMS | Colon cleansing compositions |
Sep, 2024
(8 months ago) | |
Market Authorisation Date: 02 August, 2006
Treatment: NA
Dosage: FOR SOLUTION
How can I launch a generic of MOVIPREP before it's drug patent expiration?
More Information on Dosage
MOVIPREP family patents
113. Mulpleta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7601746 | VANCOCIN ITALIA | Compounds exhibiting thrombopoietin receptor agonism |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2023 |
Drugs and Companies using LUSUTROMBOPAG ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 31 July, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
Dosage: TABLET
More Information on Dosage
MULPLETA family patents
114. Myfembree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9346822 | SUMITOMO PHARMA | Thienopyrimidine compounds and use thereof |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 26, 2024 |
| New Indication(I-898) | Aug 05, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
| M(M-289) | Jan 27, 2026 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 26 May, 2021
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women
Dosage: TABLET
More Information on Dosage
MYFEMBREE family patents
115. Myrbetriq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 26 days ago) | |
|
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 26 days ago) | |
|
US8835474 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(1 year, 26 days ago) | |
|
USRE44872 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(1 year, 26 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
| New Indication(I-777) | Apr 27, 2021 |
| New Indication(I-855) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of MYRBETRIQ before it's drug patent expiration?
More Information on Dosage
MYRBETRIQ family patents
116. Myrbetriq Granules patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 26 days ago) | |
|
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(1 year, 26 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 25 March, 2021
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
MYRBETRIQ GRANULES family patents
117. Naloxone Hydrochloride (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7918823 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US9056170 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8608698 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8313466 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US10737028 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US9737669 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8425462 | KALEO INC | Devices, systems, and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US8361029 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
| US10314977 | KALEO INC | Devices, systems and methods for medicament delivery |
Nov, 2024
(6 months ago) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 February, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
NALOXONE HYDROCHLORIDE (AUTOINJECTOR) family patents
118. Naropin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8162915 | FRESENIUS KABI USA | Connector for packings containing medical liquids, and corresponding packing for medical liquids |
May, 2024
(1 year, 7 days ago) | |
Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 January, 2011
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of NAROPIN before it's drug patent expiration?
More Information on Dosage
NAROPIN family patents
119. Nascobal patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9415007 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Jul, 2024
(10 months ago) | |
| US7229636 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(9 months ago) | |
| US7404489 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Mar, 2024
(1 year, 2 months ago) | |
| US7879349 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(9 months ago) | |
| US8003353 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Aug, 2024
(9 months ago) | |
| US8940714 | ENDO OPERATIONS | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
Feb, 2024
(1 year, 3 months ago) | |
Drugs and Companies using CYANOCOBALAMIN ingredient
Market Authorisation Date: 31 January, 2005
Treatment: Supplement for vitamin b12 deficiencies; Nasal administration of cyanocobalamin; Cyanocobalamin administration through nasal infusion
Dosage: SPRAY, METERED
How can I launch a generic of NASCOBAL before it's drug patent expiration?
More Information on Dosage
NASCOBAL family patents
120. Natesto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8784882 | ACERUS | Controlled release delivery system for nasal applications and method of treatment |
Feb, 2024
(1 year, 3 months ago) | |
| US8877230 | ACERUS | Controlled release delivery system for nasal applications |
Feb, 2024
(1 year, 3 months ago) | |
| US8784869 | ACERUS | Controlled release delivery system for nasal applications and methods of treatment |
Feb, 2024
(1 year, 3 months ago) | |
| US8574622 | ACERUS | Controlled release delivery system for nasal applications |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 28, 2017 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 28 May, 2014
Treatment: A method of testosterone replacement therapy comprising the step of nasally administering to a patient in need of such treatment an effective amount of testosterone gel formulation.; Nasal administrat...
Dosage: GEL, METERED
More Information on Dosage
NATESTO family patents
121. Ninlaro patent expiration
NINLARO's oppositions filed in EPO
Can you believe NINLARO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546608 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9233115 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2022 |
| Orphan Drug Exclusivity(ODE-103) | Nov 20, 2022 |
Drugs and Companies using IXAZOMIB CITRATE ingredient
NCE-1 date: 21 November, 2019
Market Authorisation Date: 20 November, 2015
Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
Dosage: CAPSULE
How can I launch a generic of NINLARO before it's drug patent expiration?
More Information on Dosage
NINLARO family patents
122. Nocdurna patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7560429 | FERRING PHARMS INC | Orodispersible dosage forms of desmopressin acetate |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 21, 2021 |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 21 June, 2018
Treatment: Treatment of nocturia due to nocturnal polyuria in adults
Dosage: TABLET
More Information on Dosage
NOCDURNA family patents
123. Noctiva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7799761 | ACERUS PHARMS | Pharmaceutical compositions including low dosages of desmopressin |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 03, 2020 |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 03 March, 2017
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
NOCTIVA family patents
124. Norditropin Flexpro patent expiration
NORDITROPIN FLEXPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 23 January, 2015
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN FLEXPRO family patents
125. Norditropin Flexpro patent expiration
NORDITROPIN FLEXPRO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-572) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | May 31, 2014 |
Drugs and Companies using SOMATROPIN ingredient
Market Authorisation Date: 23 January, 2015
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NORDITROPIN FLEXPRO family patents
126. Norvir patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8691878 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-184) | Jun 07, 2024 |
Drugs and Companies using RITONAVIR ingredient
Market Authorisation Date: 10 February, 2010
Treatment: Treatment of hiv-infection in combination with other antiretroviral agents
Dosage: TABLET
How can I launch a generic of NORVIR before it's drug patent expiration?
More Information on Dosage
NORVIR family patents
127. Nourianz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7541363 | KYOWA KIRIN | Microcrystal |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2024 |
Drugs and Companies using ISTRADEFYLLINE ingredient
NCE-1 date: 28 August, 2023
Market Authorisation Date: 27 August, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
NOURIANZ family patents
128. Novolog Flexpen patent expiration
NOVOLOG FLEXPEN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NOVOLOG FLEXPEN family patents
129. Novolog Flextouch patent expiration
NOVOLOG FLEXTOUCH's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NOVOLOG FLEXTOUCH family patents
130. Novolog Mix 70/30 Flexpen patent expiration
NOVOLOG MIX 70/30 FLEXPEN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
Market Authorisation Date: 01 November, 2001
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NOVOLOG MIX 70/30 FLEXPEN family patents
131. Novolog Penfill patent expiration
NOVOLOG PENFILL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
NOVOLOG PENFILL family patents
132. Nucynta Er patent expiration
NUCYNTA ER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114383 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Oct, 2024
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Dosage Form(NDF) | Aug 25, 2014 |
| New Indication(I-656) | Aug 28, 2015 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 25 August, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of NUCYNTA ER before it's drug patent expiration?
More Information on Dosage
NUCYNTA ER family patents
133. Nuplazid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028944 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 4 months ago) | |
| US8921393 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 4 months ago) | |
| US8618130 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 4 months ago) | |
| US9566271 | ACADIA PHARMS INC | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 29, 2021 |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
NCE-1 date: 29 April, 2020
Market Authorisation Date: 28 June, 2018
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis; Treatment of a neurodegenerative disease or a symptom thereof; Treatment of psychosis or a symptom thereof
Dosage: TABLET; CAPSULE
How can I launch a generic of NUPLAZID before it's drug patent expiration?
More Information on Dosage
NUPLAZID family patents
134. Nuvigil patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7132570 (Pediatric) | NUVO PHARMS | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Jun, 2024
(11 months ago) | |
|
US7297346 (Pediatric) | NUVO PHARMS | Pharmaceutical formulations of modafinil |
May, 2024
(1 year, 1 day ago) | |
Drugs and Companies using ARMODAFINIL ingredient
Market Authorisation Date: 15 June, 2007
Treatment: NA
Dosage: TABLET
How can I launch a generic of NUVIGIL before it's drug patent expiration?
More Information on Dosage
NUVIGIL family patents
135. Nymalize patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8517997 | AZURITY | Dispenser for medicaments and method and apparatus for making same |
May, 2024
(1 year, 16 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 10, 2020 |
| Orphan Drug Exclusivity(ODE-46) | May 10, 2020 |
Drugs and Companies using NIMODIPINE ingredient
Market Authorisation Date: 10 May, 2013
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of NYMALIZE before it's drug patent expiration?
More Information on Dosage
NYMALIZE family patents
136. Ofev patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7119093 | BOEHRINGER INGELHEIM | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
Feb, 2024
(1 year, 3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7989474 | BOEHRINGER INGELHEIM | Use of Lck inhibitors for treatment of immunologic diseases |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 15, 2019 |
| Orphan Drug Exclusivity(ODE) | Oct 15, 2021 |
| Orphan Drug Exclusivity(ODE-77) | Oct 15, 2021 |
| New Indication(I-805) | Sep 06, 2022 |
| New Indication(I-825) | Mar 09, 2023 |
| Orphan Drug Exclusivity(ODE-261) | Sep 06, 2026 |
| Pediatric Exclusivity(PED) | Mar 06, 2027 |
Drugs and Companies using NINTEDANIB ESYLATE ingredient
NCE-1 date: 06 March, 2026
Market Authorisation Date: 15 October, 2014
Treatment: Treatment of idiopathic pulmonary fibrosis (ipf)
Dosage: CAPSULE
How can I launch a generic of OFEV before it's drug patent expiration?
More Information on Dosage
OFEV family patents
137. Omegaven patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10350186 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2023 |
| Orphan Drug Exclusivity(ODE-202) | Jul 27, 2025 |
Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient
NCE-1 date: 27 July, 2022
Market Authorisation Date: 27 July, 2018
Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12
Dosage: EMULSION
More Information on Dosage
OMEGAVEN family patents
138. Omidria patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8173707 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(1 year, 3 months ago) | |
|
US8586633 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(1 year, 3 months ago) | |
|
US9278101 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(1 year, 3 months ago) | |
|
US9399040 (Pediatric) | RAYNER SURGICAL | Ophthalmologic irrigation solutions and method |
Jan, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2017 |
| New Patient Population(NPP) | Dec 08, 2020 |
| Pediatric Exclusivity(PED) | Jun 08, 2021 |
Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2014
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of OMIDRIA before it's drug patent expiration?
More Information on Dosage
OMIDRIA family patents
139. Omontys patent expiration
Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 18 days ago) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 18 days ago) | |
| US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 18 days ago) | |
| US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(1 year, 18 days ago) | |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION
More Information on Dosage
OMONTYS family patents
140. Omontys Preservative Free patent expiration
Can you believe OMONTYS PRESERVATIVE FREE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 18 days ago) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 18 days ago) | |
| US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(1 year, 18 days ago) | |
| US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(1 year, 18 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2017 |
Drugs and Companies using PEGINESATIDE ACETATE ingredient
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION
More Information on Dosage
OMONTYS PRESERVATIVE FREE family patents
141. Onzetra Xsail patent expiration
ONZETRA XSAIL's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9119932 | CURRAX | Nasal delivery device |
Apr, 2024
(1 year, 1 month ago) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: NA
Dosage: POWDER
More Information on Dosage
ONZETRA XSAIL family patents
142. Opana Er patent expiration
OPANA ER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114383 | ENDO PHARMS | Abuse-proofed dosage form |
Aug, 2024
(9 months ago) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 December, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OPANA ER family patents
143. Oracea patent expiration
ORACEA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8709478 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(1 year, 1 month ago) | |
| US8394405 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(1 year, 1 month ago) | |
| US8470364 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(1 year, 1 month ago) | |
| US8394406 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(1 year, 1 month ago) | |
Drugs and Companies using DOXYCYCLINE ingredient
Market Authorisation Date: 26 May, 2006
Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea
Dosage: CAPSULE
How can I launch a generic of ORACEA before it's drug patent expiration?
More Information on Dosage
ORACEA family patents
144. Orenitram patent expiration
ORENITRAM's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9050311 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 6 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7544713 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2024
(10 months ago) | |
| US9278901 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 6 days ago) | |
| US9422223 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 6 days ago) | |
| US8252839 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 6 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Dosing Schedule(D-156) | Jan 28, 2019 |
| New Dosing Schedule(D-157) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
| New Indication(I-820) | Oct 18, 2022 |
| Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of ORENITRAM before it's drug patent expiration?
More Information on Dosage
ORENITRAM family patents
145. Orgovyx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735401 | SUMITOMO PHARMA | Thienopyrimidine compounds and use thereof |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent
Dosage: TABLET
More Information on Dosage
ORGOVYX family patents
146. Oriahnn (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7056927 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
NCE-1 date: 23 July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of ORIAHNN (COPACKAGED) before it's drug patent expiration?
More Information on Dosage
ORIAHNN (COPACKAGED) family patents
147. Orilissa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7056927 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Sep, 2024
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7176211 | ABBVIE | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
Jul, 2024
(10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 23 July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis
Dosage: TABLET
How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage
ORILISSA family patents
148. Osphena patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470890 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 3 months ago) | |
| US9855224 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 3 months ago) | |
| US9241915 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 3 months ago) | |
| US8772353 | DUCHESNAY | Method for enhancing the bioavalability of ospemifene |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2018 |
| New Indication(I-793) | Jan 25, 2022 |
Drugs and Companies using OSPEMIFENE ingredient
NCE-1 date: 26 February, 2017
Market Authorisation Date: 26 February, 2013
Treatment: Treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; Treatment of moderate to severe vaginal dryness and pain with...
Dosage: TABLET
How can I launch a generic of OSPHENA before it's drug patent expiration?
More Information on Dosage
OSPHENA family patents
149. Oxaydo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9492443 | ZYLA | Abuse deterrent compositions and methods of making same |
May, 2024
(1 year, 4 days ago) | |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2011
Treatment: NA
Dosage: TABLET
How can I launch a generic of OXAYDO before it's drug patent expiration?
More Information on Dosage
OXAYDO family patents
150. Oxycontin patent expiration
OXYCONTIN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114383 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Oct, 2024
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-153) | Apr 16, 2016 |
| New Patient Population(NPP) | Aug 13, 2018 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2010
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
OXYCONTIN family patents
151. Ozempic patent expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
OZEMPIC's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Indication(I-961) | Jan 28, 2028 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage
OZEMPIC family patents
152. Pataday Once Daily Relief patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6995186 (Pediatric) | ALCON LABS INC | Olopatadine formulations for topical administration |
May, 2024
(1 year, 18 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2018 |
| Pediatric Exclusivity(PED) | Jul 30, 2018 |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 December, 2004
Treatment: NA
Dosage: SOLUTION/DROPS
How can I launch a generic of PATADAY ONCE DAILY RELIEF before it's drug patent expiration?
More Information on Dosage
PATADAY ONCE DAILY RELIEF family patents
153. Pepaxto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6992207 | ONCOPEPTIDES AB | Melphalan derivatives and their use as cancer chemotherapeutic drugs |
Jun, 2024
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2026 |
| Orphan Drug Exclusivity(ODE-348) | Feb 26, 2028 |
Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient
NCE-1 date: 26 February, 2025
Market Authorisation Date: 26 February, 2021
Treatment: In combination with dexamethasone to treat relapsed or refractory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received ...
Dosage: POWDER
More Information on Dosage
PEPAXTO family patents
154. Phexxi patent expiration
Can you believe PHEXXI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6706276 | EVOFEM INC | Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 22, 2023 |
Drugs and Companies using CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE ingredient
Market Authorisation Date: 22 May, 2020
Treatment: NA
Dosage: GEL
How can I launch a generic of PHEXXI before it's drug patent expiration?
More Information on Dosage
PHEXXI family patents
155. Ponvory patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9000018 | VANDA PHARMS INC | Thiazolidin-4-one-derivatives |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive dise...
Dosage: TABLET
More Information on Dosage
PONVORY family patents
156. Prevymis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7196086 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(1 year, 8 days ago) | |
| US8513255 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(1 year, 8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 08, 2022 |
| Orphan Drug Exclusivity(ODE-165) | Nov 08, 2024 |
| New Indication(I-916) | Jun 05, 2026 |
| New Dosing Schedule(D-189) | Aug 02, 2026 |
| New Product(NP) | Aug 30, 2027 |
| New Patient Population(NPP) | Aug 30, 2027 |
| ODE*(ODE*) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-423) | Jun 05, 2030 |
| Orphan Drug Exclusivity(ODE-495) | Aug 30, 2031 |
| Orphan Drug Exclusivity(ODE-497) | Aug 30, 2031 |
Drugs and Companies using LETERMOVIR ingredient
NCE-1 date: 08 November, 2021
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: TABLET; SOLUTION
More Information on Dosage
PREVYMIS family patents
157. Prezcobix patent expiration
PREZCOBIX's oppositions filed in EPO
PREZCOBIX IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(1 year, 3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 21 March, 2025
Treatment: NA
Dosage: TABLET
More Information on Dosage
PREZCOBIX family patents
158. Prezista patent expiration
PREZISTA's oppositions filed in EPO
PREZISTA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(1 year, 3 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8518987 (Pediatric) | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-118) | Oct 21, 2011 |
| New Indication(I-578) | Oct 21, 2011 |
| New Dosing Schedule(D-119) | Dec 18, 2011 |
| New Strength(NS) | Dec 18, 2011 |
| New Dosing Schedule(D-129) | Dec 13, 2013 |
| Pediatric Exclusivity(PED) | Aug 01, 2016 |
| New Dosage Form(NDF) | Dec 16, 2014 |
| New Patient Population(NPP) | Dec 16, 2014 |
| New Dosing Schedule(D-135) | Feb 01, 2016 |
Drugs and Companies using DARUNAVIR ingredient
Market Authorisation Date: 18 December, 2008
Treatment: NA
Dosage: TABLET; SUSPENSION
How can I launch a generic of PREZISTA before it's drug patent expiration?
More Information on Dosage
PREZISTA family patents
159. Prialt patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8653033 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(7 months ago) | |
| US9707270 | TERSERA | Method for administering ω-conopeptide |
Oct, 2024
(7 months ago) | |
| US8765680 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(7 months ago) | |
Drugs and Companies using ZICONOTIDE ACETATE ingredient
Market Authorisation Date: 28 December, 2004
Treatment: Analgesia; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine; Treatment of pain
Dosage: INJECTABLE
More Information on Dosage
PRIALT family patents
160. Probuphine patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7736665 | REACX PHARMS | Implantable polymeric device for sustained release of buprenorphine |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 26, 2019 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 26 May, 2016
Treatment: For opioid dependence
Dosage: IMPLANT
More Information on Dosage
PROBUPHINE family patents
161. Prolensa patent expiration
PROLENSA's oppositions filed in EPO
PROLENSA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8927606 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 4 months ago) | |
| US8754131 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 4 months ago) | |
| US8871813 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 4 months ago) | |
| US9144609 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 4 months ago) | |
| US8669290 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 4 months ago) | |
| US9561277 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2016 |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: Method of treating ocular inflammation; Treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery
Dosage: SOLUTION/DROPS
How can I launch a generic of PROLENSA before it's drug patent expiration?
More Information on Dosage
PROLENSA family patents
162. Protonix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7553498 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(7 months ago) | |
| US7838027 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(7 months ago) | |
| US7550153 | WYETH PHARMS | Pantoprazole multiparticulate formulations |
Sep, 2024
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-614) | Nov 12, 2012 |
| M(M-54) | Nov 12, 2012 |
| Pediatric Exclusivity(PED) | May 12, 2013 |
Drugs and Companies using PANTOPRAZOLE SODIUM ingredient
Market Authorisation Date: 14 November, 2007
Treatment: Erosive esophagitis, hypersecretory conditions including zollinger-ellison syndrome, maintenance of healing of erosive esophagitis and reduction of symptoms in patients with gerd
Dosage: FOR SUSPENSION, DELAYED RELEASE
How can I launch a generic of PROTONIX before it's drug patent expiration?
More Information on Dosage
PROTONIX family patents
163. Provigil patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7297346 (Pediatric) | NUVO PHARMS | Pharmaceutical formulations of modafinil |
May, 2024
(1 year, 1 day ago) | |
Drugs and Companies using MODAFINIL ingredient
Market Authorisation Date: 24 December, 1998
Treatment: NA
Dosage: TABLET
How can I launch a generic of PROVIGIL before it's drug patent expiration?
More Information on Dosage
PROVIGIL family patents
164. Rayos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309124 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(1 year, 1 month ago) | |
| US8394407 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(1 year, 1 month ago) | |
| US9186332 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(1 year, 1 month ago) | |
| US9040085 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Jul 26, 2015 |
Drugs and Companies using PREDNISONE ingredient
Market Authorisation Date: 26 July, 2012
Treatment: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet
Dosage: TABLET, DELAYED RELEASE
How can I launch a generic of RAYOS before it's drug patent expiration?
More Information on Dosage
RAYOS family patents
165. Relistor patent expiration
RELISTOR's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376584 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(1 year, 1 month ago) | |
| US8552025 | SALIX PHARMS | Stable methylnaltrexone preparation |
Apr, 2024
(1 year, 1 month ago) | |
| US9669096 | SALIX PHARMS | Stable pharmaceutical formulations of methylnaltrexone |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
| New Product(NP) | Jul 19, 2019 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
NCE-1 date: 24 April, 2012
Market Authorisation Date: 27 September, 2010
Treatment: Treatment of opioid-induced constipation
Dosage: SOLUTION
How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage
RELISTOR family patents
166. Remodulin patent expiration
REMODULIN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9199908 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(1 year, 6 days ago) | |
| US9713599 | UNITED THERAP | Parenteral formulations of treprostinil |
Dec, 2024
(5 months ago) | |
| US10695308 | UNITED THERAP | Inhalation formulations of treprostinil |
Dec, 2024
(5 months ago) | |
| US10076505 | UNITED THERAP | Inhalation formulations of Treprostinil |
Dec, 2024
(5 months ago) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 28 September, 2023
Treatment: Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration; A method of treating pulmonary hypertension co...
Dosage: INJECTABLE; SOLUTION
How can I launch a generic of REMODULIN before it's drug patent expiration?
More Information on Dosage
REMODULIN family patents
167. Restasis patent expiration
RESTASIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
| US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
| US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
| US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
| US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
| US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION
How can I launch a generic of RESTASIS before it's drug patent expiration?
More Information on Dosage
RESTASIS family patents
168. Restasis Multidose patent expiration
RESTASIS MULTIDOSE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
| US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
| US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
| US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
| US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
| US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(9 months ago) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION
How can I launch a generic of RESTASIS MULTIDOSE before it's drug patent expiration?
More Information on Dosage
RESTASIS MULTIDOSE family patents
169. Revlimid patent expiration
REVLIMID's oppositions filed in EPO
Can you believe REVLIMID received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7855217 | BRISTOL MYERS SQUIBB | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jun 05, 2020 |
| New Indication(I-672) | Jun 05, 2016 |
| New Strength(NS) | Jun 05, 2016 |
| New Indication(I-706) | Feb 17, 2018 |
| Orphan Drug Exclusivity(ODE-49) | Jun 05, 2020 |
| Orphan Drug Exclusivity(ODE-88) | Feb 17, 2022 |
| New Indication(I-796) | May 28, 2022 |
| New Indication(I-797) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-131) | Feb 22, 2024 |
| Orphan Drug Exclusivity(ODE-241) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-245) | May 28, 2026 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 21 December, 2011
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of REVLIMID before it's drug patent expiration?
More Information on Dosage
REVLIMID family patents
170. Rhofade patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420688 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Aug, 2024
(9 months ago) | |
| US8815929 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 18, 2020 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream
Dosage: CREAM
How can I launch a generic of RHOFADE before it's drug patent expiration?
More Information on Dosage
RHOFADE family patents
171. Robinul patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7091236 | CASPER PHARMA LLC | Method for increasing the bioavailability of glycopyrrolate |
Apr, 2024
(1 year, 1 month ago) | |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 01 January, 1982
Treatment: For use as adjunctive therapy in the treatment of peptic ulcer
Dosage: TABLET
How can I launch a generic of ROBINUL before it's drug patent expiration?
More Information on Dosage
ROBINUL family patents
172. Robinul Forte patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7091236 | CASPER PHARMA LLC | Method for increasing the bioavailability of glycopyrrolate |
Apr, 2024
(1 year, 1 month ago) | |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 01 January, 1982
Treatment: For use as adjunctive therapy in the treatment of peptic ulcer
Dosage: TABLET
How can I launch a generic of ROBINUL FORTE before it's drug patent expiration?
More Information on Dosage
ROBINUL FORTE family patents
173. Rubraca patent expiration
RUBRACA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7351701 | PHARMAAND | Therapeutic compounds |
Jul, 2024
(10 months ago) | |
| US7531530 | PHARMAAND | Therapeutic compounds |
Jul, 2024
(10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-772) | Apr 06, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2021 |
| New Indication(I-830) | May 15, 2023 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2023 |
| Orphan Drug Exclusivity(ODE-126) | Dec 19, 2023 |
| Orphan Drug Exclusivity(ODE-168) | Apr 06, 2025 |
Drugs and Companies using RUCAPARIB CAMSYLATE ingredient
NCE-1 date: 19 December, 2020
Market Authorisation Date: 19 December, 2016
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation
Dosage: TABLET
More Information on Dosage
RUBRACA family patents
174. Ryzodeg 70/30 patent expiration
RYZODEG 70/30's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN ASPART; INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 25 September, 2015
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
RYZODEG 70/30 family patents
175. Sanctura Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7781449 | ALLERGAN | Trospium chloride treatment method |
Nov, 2024
(6 months ago) | |
| US7781448 | ALLERGAN | Once daily dosage forms of trospium |
Nov, 2024
(6 months ago) | |
| US7759359 | ALLERGAN | Method of treating bladder dysfunction with once-a-day trospium salt formulation |
Nov, 2024
(6 months ago) | |
| US7763635 | ALLERGAN | Once daily dosage forms of trospium |
Nov, 2024
(6 months ago) | |
Drugs and Companies using TROSPIUM CHLORIDE ingredient
Market Authorisation Date: 03 August, 2007
Treatment: Method of treating bladder dysfunction with once a day trospium salt formulation
Dosage: CAPSULE, EXTENDED RELEASE
How can I launch a generic of SANCTURA XR before it's drug patent expiration?
More Information on Dosage
SANCTURA XR family patents
176. Saxenda patent expiration
SAXENDA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
|
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| New Product(NP) | Jan 25, 2017 |
| New Patient Population(NPP) | Dec 04, 2023 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage
SAXENDA family patents
177. Seasonique patent expiration
SEASONIQUE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320969 | TEVA BRANDED PHARM | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
Jan, 2024
(1 year, 3 months ago) | |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 25 May, 2006
Treatment: Prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET
How can I launch a generic of SEASONIQUE before it's drug patent expiration?
More Information on Dosage
SEASONIQUE family patents
178. Sinuva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8109918 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(1 year, 2 months ago) | |
| US7662141 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(1 year, 2 months ago) | |
| US7713255 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(1 year, 2 months ago) | |
| US7951133 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(1 year, 2 months ago) | |
| US7951131 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(1 year, 2 months ago) | |
| US7951130 | INTERSECT ENT INC | Sinus delivery of sustained release therapeutics |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 08, 2020 |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 08 December, 2017
Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant
Dosage: IMPLANT
More Information on Dosage
SINUVA family patents
179. Soliqua 100/33 patent expiration
SOLIQUA 100/33 IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9827379 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9775954 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US8992486 | SANOFI-AVENTIS US | Pen-type injector |
Jun, 2024
(11 months ago) | |
| US9011391 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9561331 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9604009 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9604008 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9408979 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9233211 | SANOFI-AVENTIS US | Relating to a pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9526844 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US8603044 | SANOFI-AVENTIS US | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9533105 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US8512297 | SANOFI-AVENTIS US | Pen-type injector |
Sep, 2024
(8 months ago) | |
| US8556864 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9623189 | SANOFI-AVENTIS US | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9610409 | SANOFI-AVENTIS US | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using INSULIN GLARGINE; LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 21 November, 2016
Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glycemic control in adults with type 2 diabetes mellitus by use of a...
Dosage: SOLUTION
More Information on Dosage
SOLIQUA 100/33 family patents
180. Soolantra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470788 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 1 month ago) | |
| US7550440 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 1 month ago) | |
| US8815816 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 1 month ago) | |
| US8093219 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 1 month ago) | |
| US8080530 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 1 month ago) | |
| US8415311 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 1 month ago) | |
| US11033565 | GALDERMA LABS LP | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 19, 2017 |
Drugs and Companies using IVERMECTIN ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of inflammatory lesions of rosacea
Dosage: CREAM
How can I launch a generic of SOOLANTRA before it's drug patent expiration?
More Information on Dosage
SOOLANTRA family patents
181. Spiriva Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 15, 2018 |
| New Patient Population(NPP) | Feb 15, 2020 |
| Pediatric Exclusivity(PED) | Aug 15, 2020 |
Drugs and Companies using TIOTROPIUM BROMIDE ingredient
Market Authorisation Date: 15 September, 2015
Treatment: NA
Dosage: SPRAY, METERED
How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage
SPIRIVA RESPIMAT family patents
182. Stiolto Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 21, 2018 |
| M(M-173) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
| M(M-233) | Oct 05, 2021 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 21 May, 2015
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
STIOLTO RESPIMAT family patents
183. Stribild patent expiration
STRIBILD's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8716264 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jul, 2024
(10 months ago) | |
| US9744181 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US9457036 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US8716264 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US8592397 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 27, 2015 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Indication(I-704) | Dec 17, 2017 |
| New Patient Population(NPP) | Jan 27, 2020 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of STRIBILD before it's drug patent expiration?
More Information on Dosage
STRIBILD family patents
184. Striverdi Respimat patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2019 |
Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2018
Market Authorisation Date: 31 July, 2014
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
STRIVERDI RESPIMAT family patents
185. Suboxone patent expiration
SUBOXONE's oppositions filed in EPO
SUBOXONE IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8603514 | INDIVIOR | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 30, 2013 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 August, 2010
Treatment: Treatment of opioid dependence/sublingual or buccal application
Dosage: FILM
How can I launch a generic of SUBOXONE before it's drug patent expiration?
More Information on Dosage
SUBOXONE family patents
186. Sumavel Dosepro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8287489 | ENDO OPERATIONS | Device for readying a needle free injector for delivery |
Dec, 2024
(5 months ago) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 26 November, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
SUMAVEL DOSEPRO family patents
187. Sustol patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357570 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(8 months ago) | |
| US8252305 | HERON THERAPS INC | Methods of treating emesis utilizing semi-solid delivery pharmaceutical compositions comprising granisetron |
Sep, 2024
(8 months ago) | |
| US8715710 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(8 months ago) | |
| US8252304 | HERON THERAPS INC | Semi-solid delivery vehicle and pharmaceutical compositions for delivery of granisetron |
Sep, 2024
(8 months ago) | |
| US9913910 | HERON THERAPS INC | Methods of treating nausea utilizing semi-solid delivery vehicle compositions comprising granisetron |
Sep, 2024
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 09, 2019 |
Drugs and Companies using GRANISETRON ingredient
Market Authorisation Date: 09 August, 2016
Treatment: Prophylactic treatment of nausea and vomiting, including prevention of acute and delayed nausea and vomiting associated chemotherapy; Treatment or prevention of nausea and vomiting
Dosage: INJECTABLE
More Information on Dosage
SUSTOL family patents
188. Symbicort patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8875699 | ASTRAZENECA | Inhaler cap strap |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-582) | Feb 27, 2012 |
| New Patient Population(NPP) | Jan 27, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
| M(M-210) | Sep 11, 2020 |
| M(M-214) | Dec 20, 2020 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date: 21 July, 2006
Treatment: NA
Dosage: AEROSOL, METERED
How can I launch a generic of SYMBICORT before it's drug patent expiration?
More Information on Dosage
SYMBICORT family patents
189. Sympazan patent expiration
SYMPAZAN's oppositions filed in EPO
SYMPAZAN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765167 | OTTER PHARMS | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(1 year, 3 months ago) | |
| US8603514 | OTTER PHARMS | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(1 year, 1 month ago) | |
Drugs and Companies using CLOBAZAM ingredient
Market Authorisation Date: 01 November, 2018
Treatment: NA
Dosage: FILM
More Information on Dosage
SYMPAZAN family patents
190. Symtuza patent expiration
SYMTUZA's oppositions filed in EPO
SYMTUZA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: NA
Dosage: TABLET
How can I launch a generic of SYMTUZA before it's drug patent expiration?
More Information on Dosage
SYMTUZA family patents
191. Tasigna patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7169791 (Pediatric) | NOVARTIS | Inhibitors of tyrosine kinases |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2012 |
| New Indication(I-627) | Jun 17, 2014 |
| Orphan Drug Exclusivity(ODE) | Oct 29, 2014 |
| New Dosing Schedule(D-170) | Dec 22, 2020 |
| New Patient Population(NPP) | Mar 22, 2021 |
| Orphan Drug Exclusivity(ODE-171) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-172) | Mar 22, 2025 |
| Orphan Drug Exclusivity(ODE-380) | Sep 23, 2028 |
| Pediatric Exclusivity(PED) | Mar 23, 2029 |
Drugs and Companies using NILOTINIB HYDROCHLORIDE ingredient
NCE-1 date: 23 March, 2028
Market Authorisation Date: 22 March, 2018
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of TASIGNA before it's drug patent expiration?
More Information on Dosage
TASIGNA family patents
192. Technivie patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-743) | Jul 24, 2018 |
| New Product(NP) | Jul 24, 2018 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 24 July, 2015
Treatment: NA
Dosage: TABLET
More Information on Dosage
TECHNIVIE family patents
193. Tirosint patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7723390 | INST BIOCHIMIQUE | Pharmaceutical formulations for thyroid hormones |
Mar, 2024
(1 year, 2 months ago) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 01 August, 2007
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of TIROSINT before it's drug patent expiration?
More Information on Dosage
TIROSINT family patents
194. Tirosint patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7723390 | IBSA | Pharmaceutical formulations for thyroid hormones |
Mar, 2024
(1 year, 2 months ago) | |
| US7691411 | IBSA | Pharmaceutical formulae for thyroid hormones and procedures for obtaining them |
Mar, 2024
(1 year, 2 months ago) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 01 August, 2007
Treatment: NA
Dosage: CAPSULE
How can I launch a generic of TIROSINT before it's drug patent expiration?
More Information on Dosage
TIROSINT family patents
195. Tobi Podhaler patent expiration
TOBI PODHALER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8069851 | VIATRIS | Aeorosolization apparatus with air inlet shield |
Sep, 2024
(8 months ago) | |
| US11484671 | VIATRIS | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2024
(6 months ago) | |
| USRE47526 | VIATRIS | Aerosolization apparatus with air inlet shield |
Apr, 2024
(1 year, 1 month ago) | |
| US7516741 | VIATRIS | Aerosolization apparatus with feedback mechanism |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2016 |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER
More Information on Dosage
TOBI PODHALER family patents
196. Torisel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8455539 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(1 year, 4 months ago) | |
|
US8722700 (Pediatric) | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jan, 2024
(1 year, 4 months ago) | |
|
US8299116 (Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-91) | Apr 26, 2013 |
| M(M-92) | Jul 09, 2013 |
| Pediatric Exclusivity(PED) | Jan 09, 2014 |
| Orphan Drug Exclusivity(ODE) | May 30, 2014 |
| M(M-61) | May 30, 2015 |
Drugs and Companies using TEMSIROLIMUS ingredient
Market Authorisation Date: 30 May, 2007
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of TORISEL before it's drug patent expiration?
More Information on Dosage
TORISEL family patents
197. Toujeo Max Solostar patent expiration
TOUJEO MAX SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9526844 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9604009 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9775954 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US8992486 | SANOFI US SERVICES | Pen-type injector |
Jun, 2024
(11 months ago) | |
| US9011391 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9827379 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9561331 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US8512297 | SANOFI US SERVICES | Pen-type injector |
Sep, 2024
(8 months ago) | |
| US9623189 | SANOFI US SERVICES | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9604008 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US8556864 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9233211 | SANOFI US SERVICES | Relating to a pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9533105 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9610409 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9408979 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US8603044 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve; Improvement in glycemic control in diabetes mellitus patients by use of a pen injec...
Dosage: SOLUTION
More Information on Dosage
TOUJEO MAX SOLOSTAR family patents
198. Toujeo Solostar patent expiration
TOUJEO SOLOSTAR IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9561331 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US8512297 | SANOFI US SERVICES | Pen-type injector |
Sep, 2024
(8 months ago) | |
| US9533105 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US8556864 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9011391 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9827379 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9775954 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9408979 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9233211 | SANOFI US SERVICES | Relating to a pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9604008 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US8992486 | SANOFI US SERVICES | Pen-type injector |
Jun, 2024
(11 months ago) | |
| US9610409 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(1 year, 2 months ago) | |
| US9623189 | SANOFI US SERVICES | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US9526844 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| US9604009 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(9 months ago) | |
| US8603044 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve; Improvement in glycemic control in diabetes mellitus patients by use of a pen injec...
Dosage: SOLUTION
More Information on Dosage
TOUJEO SOLOSTAR family patents
199. Tpoxx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8124643 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802714 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(11 months ago) | |
| US8530509 | SIGA TECHNOLOGIES | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun, 2024
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 13, 2023 |
| Orphan Drug Exclusivity(ODE-200) | Jul 13, 2025 |
Drugs and Companies using TECOVIRIMAT ingredient
NCE-1 date: 13 July, 2022
Market Authorisation Date: 13 July, 2018
Treatment: Tpoxx is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg
Dosage: CAPSULE; SOLUTION
More Information on Dosage
TPOXX family patents
200. Tresiba patent expiration
TRESIBA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
Drugs and Companies using INSULIN DEGLUDEC ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
TRESIBA family patents
201. Truvada patent expiration
TRUVADA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8716264 (Pediatric) | GILEAD | Compositions and methods for combination antiviral therapy |
Jul, 2024
(10 months ago) | |
| US8592397 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US9744181 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US9457036 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
| US8716264 | GILEAD | Compositions and methods for combination antiviral therapy |
Jan, 2024
(1 year, 4 months ago) | |
Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv infection
Dosage: TABLET
How can I launch a generic of TRUVADA before it's drug patent expiration?
More Information on Dosage
TRUVADA family patents
202. Tukysa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7452895 | SEAGEN | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-906) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
| Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET
More Information on Dosage
TUKYSA family patents
203. Ulesfia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7294342 | SHIONOGI INC | Ectoparasite asphyxiator compositions and methods for their application |
May, 2024
(1 year, 11 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 09, 2014 |
Drugs and Companies using BENZYL ALCOHOL ingredient
NCE-1 date: 09 April, 2013
Market Authorisation Date: 09 April, 2009
Treatment: Topical treatment of lice infestations
Dosage: LOTION
How can I launch a generic of ULESFIA before it's drug patent expiration?
More Information on Dosage
ULESFIA family patents
204. Uloric patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7361676 | TAKEDA PHARMS USA | Solid preparation containing single crystal form |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 13, 2014 |
| M(M-205) | Aug 15, 2020 |
Drugs and Companies using FEBUXOSTAT ingredient
NCE-1 date: 13 February, 2013
Market Authorisation Date: 13 February, 2009
Treatment: NA
Dosage: TABLET
How can I launch a generic of ULORIC before it's drug patent expiration?
More Information on Dosage
ULORIC family patents
205. Vandazole patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7456207 | TEVA PHARMS | Vaginal pharmaceutical compositions and methods for preparing them |
Sep, 2024
(8 months ago) | |
Drugs and Companies using METRONIDAZOLE ingredient
Market Authorisation Date: 20 May, 2005
Treatment: NA
Dosage: GEL
More Information on Dosage
VANDAZOLE family patents
206. Varithena patent expiration
VARITHENA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7731986 | PROVENSIS | Therapeutic foam |
Nov, 2024
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8122917 | PROVENSIS | Apparatus and method for dispensing foam |
Sep, 2024
(8 months ago) | |
Drugs and Companies using POLIDOCANOL ingredient
Market Authorisation Date: 21 December, 2017
Treatment: A method of intravenous injection using ultrasound guidance, administered via a single cannula into the lumen of the target incompetent trunk veins or by direct injection into varicosities
Dosage: SOLUTION
More Information on Dosage
VARITHENA family patents
207. Veltassa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778324 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 2 months ago) | |
| US8889115 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 2 months ago) | |
| US8287847 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 2 months ago) | |
| US8475780 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 2 months ago) | |
| US10485821 | VIFOR PHARMA | Ion binding polymers and uses thereof |
Mar, 2024
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 21, 2020 |
| New Patient Population(NPP) | Oct 02, 2026 |
| New Strength(NS) | Oct 02, 2026 |
Drugs and Companies using PATIROMER SORBITEX CALCIUM ingredient
NCE-1 date: 22 October, 2019
Market Authorisation Date: 02 October, 2023
Treatment: Treatment of hyperkalemia
Dosage: POWDER
How can I launch a generic of VELTASSA before it's drug patent expiration?
More Information on Dosage
VELTASSA family patents
208. Veramyst patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9320862 | GLAXOSMITHKLINE | Fluid dispensing device |
Nov, 2024
(6 months ago) | |
Drugs and Companies using FLUTICASONE FUROATE ingredient
Market Authorisation Date: 27 April, 2007
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
VERAMYST family patents
209. Victoza patent expiration
VICTOZA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7762994 | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
|
US7762994 (Pediatric) | NOVO NORDISK INC | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| M(M-115) | Apr 06, 2015 |
| M(M-176) | Apr 22, 2019 |
| New Indication(I-750) | Aug 25, 2020 |
| New Patient Population(NPP) | Jun 17, 2022 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage
VICTOZA family patents
210. Victrelis patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43298 | MERCK SHARP DOHME | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
Dec, 2024
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 13, 2016 |
| M(M-126) | Feb 27, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 13, 2016 |
Drugs and Companies using BOCEPREVIR ingredient
NCE-1 date: 14 May, 2015
Market Authorisation Date: 13 May, 2011
Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease
Dosage: CAPSULE
More Information on Dosage
VICTRELIS family patents
211. Viekira Pak (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-163) | Apr 22, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: NA
Dosage: TABLET
More Information on Dosage
VIEKIRA PAK (COPACKAGED) family patents
212. Viekira Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8268349 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| US8399015 | ABBVIE | Solid pharmaceutical dosage form |
Aug, 2024
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 22 July, 2016
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VIEKIRA XR family patents
213. Vizamyl patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8236282 | GE HEALTHCARE | Benzothiazole derivative compounds, compositions and uses |
May, 2024
(1 year, 9 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 25, 2018 |
Drugs and Companies using FLUTEMETAMOL F-18 ingredient
NCE-1 date: 25 October, 2017
Market Authorisation Date: 25 October, 2013
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
VIZAMYL family patents
214. Xarelto patent expiration
XARELTO's oppositions filed in EPO
XARELTO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(9 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9415053 | JANSSEN PHARMS | Solid, orally administrable pharmaceutical composition |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-643) | Nov 04, 2014 |
| New Indication(I-660) | Nov 02, 2015 |
| New Indication(I-661) | Nov 02, 2015 |
| New Indication(I-662) | Nov 02, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Dosing Schedule(D-168) | Oct 27, 2020 |
| New Indication(I-824) | Oct 11, 2021 |
| New Indication(I-810) | Oct 11, 2022 |
| M(M-284) | Mar 10, 2023 |
| New Indication(I-867) | Aug 23, 2024 |
| New Product(NP) | Dec 20, 2024 |
| Pediatric Exclusivity(PED) | Jun 20, 2025 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Treatment: Treatment of venous thromboembolism (vte) and the reduction in the risk of recurrent vte in pediatric patients from birth to less than 18 years with a body weight of >=50 kg after at least 5 days of i...
Dosage: TABLET; FOR SUSPENSION
How can I launch a generic of XARELTO before it's drug patent expiration?
More Information on Dosage
XARELTO family patents
215. Xeglyze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9839631 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(10 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8212038 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(10 months ago) | |
| US9357783 | HATCHTECH | Methods and compositions for controlling ectoparasites |
Jul, 2024
(10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 24 July, 2024
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION
More Information on Dosage
XEGLYZE family patents
216. Xhance patent expiration
XHANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8522778 | OPTINOSE US INC | Nasal devices |
Apr, 2024
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
| New Indication(I-940) | Mar 15, 2027 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
XHANCE family patents
217. Xifaxan patent expiration
XIFAXAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8835452 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(11 months ago) | |
| US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(11 months ago) | |
| US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(11 months ago) | |
| US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(11 months ago) | |
| US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(11 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(11 months ago) | |
| US8158644 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(11 months ago) | |
| US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(11 months ago) | |
| US8853231 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(11 months ago) | |
| US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(11 months ago) | |
| US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 24, 2013 |
| Orphan Drug Exclusivity(ODE) | Mar 24, 2017 |
| New Indication(I-709) | May 27, 2018 |
Drugs and Companies using RIFAXIMIN ingredient
Market Authorisation Date: 24 March, 2010
Treatment: NA
Dosage: TABLET
How can I launch a generic of XIFAXAN before it's drug patent expiration?
More Information on Dosage
XIFAXAN family patents
218. Xiidra patent expiration
Can you believe XIIDRA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7928122 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(6 months ago) | |
| US7745460 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216174 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(6 months ago) | |
| US7790743 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(6 months ago) | |
| US10124000 | BAUSCH AND LOMB INC | Modulators of cellular adhesion |
Nov, 2024
(6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: Treatment of signs and symptoms of dry eye disease (ded); Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS
How can I launch a generic of XIIDRA before it's drug patent expiration?
More Information on Dosage
XIIDRA family patents
219. Xopenex Hfa patent expiration
XOPENEX HFA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7256310 | LUPIN | Levalbuterol salt |
Oct, 2024
(7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-156) | Mar 12, 2018 |
Drugs and Companies using LEVALBUTEROL TARTRATE ingredient
Market Authorisation Date: 11 March, 2005
Treatment: Treatment or prevention of bronchospasm or asthmatic symptoms
Dosage: AEROSOL, METERED
How can I launch a generic of XOPENEX HFA before it's drug patent expiration?
More Information on Dosage
XOPENEX HFA family patents
220. Xultophy 100/3.6 patent expiration
XULTOPHY 100/3.6's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7762994 (Pediatric) | NOVO | Needle mounting system and a method for mounting a needle assembly |
Nov, 2024
(6 months ago) | |
| US7762994 | NOVO | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(1 year, 7 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Nov 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Sep 25, 2020 |
| M(M-242) | Aug 08, 2022 |
Drugs and Companies using INSULIN DEGLUDEC; LIRAGLUTIDE ingredient
NCE-1 date: 26 September, 2019
Market Authorisation Date: 21 November, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
XULTOPHY 100/3.6 family patents
221. Xyrem patent expiration
XYREM IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7765107 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(5 months ago) | |
|
US7765106 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(5 months ago) | |
| US7668730 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(11 months ago) | |
|
US7668730 (Pediatric) | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2024
(5 months ago) | |
| US7765107 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(11 months ago) | |
| US7765106 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Nov 18, 2012 |
| New Patient Population(NPP) | Oct 26, 2021 |
| Orphan Drug Exclusivity(ODE-231) | Oct 26, 2025 |
| Pediatric Exclusivity(PED) | Apr 26, 2026 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 17 July, 2002
Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution; A method to control abuse of a sensitive drug by controlling with a computer proc...
Dosage: SOLUTION
How can I launch a generic of XYREM before it's drug patent expiration?
More Information on Dosage
XYREM family patents
222. Zavzpret patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7220862 | PFIZER | Calcitonin gene related peptide receptor antagonists |
Jan, 2024
(1 year, 4 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 09, 2028 |
Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2027
Market Authorisation Date: 09 March, 2023
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
ZAVZPRET family patents
223. Zmax patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6984403 | PF PRISM CV | Azithromycin dosage forms with reduced side effects |
Feb, 2024
(1 year, 3 months ago) | |
| US7887844 | PF PRISM CV | Multiparticulate crystalline drug compositions having controlled release profiles |
Feb, 2024
(1 year, 3 months ago) | |
Drugs and Companies using AZITHROMYCIN ingredient
Market Authorisation Date: 10 June, 2005
Treatment: Method of treating bacterial infections
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ZMAX family patents
224. Zolinza patent expiration
ZOLINZA's oppositions filed in EPO
Can you believe ZOLINZA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7851509 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Feb, 2024
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2011 |
| Orphan Drug Exclusivity(ODE) | Oct 06, 2013 |
Drugs and Companies using VORINOSTAT ingredient
NCE-1 date: 06 October, 2010
Market Authorisation Date: 06 October, 2006
Treatment: Treatment of cutaneous manifestations in patients with cutaneous t-cell lymphoma (ctcl)
Dosage: CAPSULE
More Information on Dosage
ZOLINZA family patents
225. Zontivity patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7713999 | KEY THERAP | Thrombin receptor antagonists |
May, 2024
(a year ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2019 |
Drugs and Companies using VORAPAXAR SULFATE ingredient
NCE-1 date: 08 May, 2018
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad)
Dosage: TABLET
More Information on Dosage
ZONTIVITY family patents